Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Item No. 20959

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

1-Oleoyl-2-hydroxy-sn-glycero-3-phosphocholine is a lysophospholipid containing oleic acid (Item Nos. 90260 | 24659) at the sn-1 position. It inhibits taurine uptake in Caco-2 cells when used at a concentration of 200 µM.1 Levels of 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine are increased in conditioned medium in VEGF-stimulated primary normal human bronchial epithelial (NHBE) cells, an effect that can be reversed by the phospholipase A2 (PLA2) inhibitor oleyloxyethyl phosphorylcholine (Item No. 70560).2 Plasma levels of 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine are decreased in patients with lung cancer or abdominal aortic aneurysm.3,4
WARNING This product is not for human or veterinary use.
1. Characteristics of lysophosphatidylcholine in its inhibition of taurine uptake by human intestinal Caco-
2. Stimulated bronchial epithelial cells release bioactive lysophosphatidylcholine 16:0, 18:0, and 18:1. Allergy Asthma Immunol. Res. 6(1), 66-74 (2014).
3. Lysophosphatidylcholine profiling of plasma: Discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 6(4), 478-488 (2010).
4. Plasma lipidomics analysis reveals the potential role of lysophosphatidylcholines in abdominal aortic aneurysm progression and formation. Int. J. Mol. Sci. 24(12), 10253 (2023).